Stealth BioTherapeutics Granted Fast Track Designation for Elamipretide for the Treatment of Dry Age-Related Macular Degeneration with Geographic Atrophy

BOSTON – December 10, 2018 – Stealth BioTherapeutics (Stealth), a clinical-stage biopharmaceutical company developing therapeutics to treat mitochondrial dysfunction, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for its lead investigational candidate, elamipretide, for the treatment of dry age-related macular degeneration (AMD) with geographic atrophy.

“We are pleased the FDA recognizes elamipretide’s potential to treat dry AMD,” said Reenie McCarthy, Chief Executive Officer at Stealth. “This regulatory support will help facilitate our efforts to address the severe vision loss that impairs the quality of life of millions of elderly patients living with this disease.” AMD is the leading cause of blindness in the elderly and dry AMD currently has no FDA-approved treatments.

In November 2016, Stealth announced the initiation of ReCLAIM, an open-label Phase 1 study to evaluate the safety and tolerability of 24 weeks’ treatment with daily subcutaneous injections of elamipretide in patients with dry AMD. In early 2019, Stealth plans to initiate a Phase 2b, randomized, double-masked, placebo-controlled clinical study to evaluate the safety and efficacy of subcutaneous injections of elamipretide in patients with dry AMD with geographic atrophy.

The FDA’s Fast Track program facilitates the development and review of drugs to treat serious conditions with unmet medical needs. The designation provides the opportunity for more frequent meetings with the FDA over the course of development and allows for rolling submission of individual sections of a New Drug Application for review. The designation also increases the likelihood of eligibility for priority review and accelerated approval if relevant criteria are met.

Elamipretide has also been granted Fast Track designation for the treatment of primary mitochondrial myopathy, Barth syndrome and Leber’s hereditary optic neuropathy, three rare primary mitochondrial diseases.

For additional information on the ReCLAIM study or elamipretide, please refer to Stealth’s website.

About Age-Related Macular Degeneration

Age-related macular degeneration (AMD), a progressive eye condition which is the leading cause of blindness in the elderly, affects approximately 10 million people in the U.S. AMD affects the center portion of the retina, called the macula, which is responsible for central vision and color perception.  Although there are FDA-approved treatments for wet AMD, which affects approximately 10 percent of those suffering from the disease, there are no approved therapies for dry AMD. Dry AMD with geographic atrophy, an advanced form of dry AMD, is characterized by central blind spots leading to permanent loss of vision.  The disease is a major contributor to loss of independence and diminished quality of life in older persons.

About Stealth

We are a privately held clinical-stage biotechnology company focused on the development of therapeutics for diseases involving mitochondrial dysfunction. We believe there is a strong rationale for our lead product candidate, elamipretide, in indications in these diseases based on encouraging preclinical and early clinical data. We are investigating elamipretide in three primary mitochondrial diseases – primary mitochondrial myopathy, Barth syndrome and Leber’s hereditary optic neuropathy – for which we have both Fast Track and Orphan Drug designations. We are also investigating elamipretide in dry age-related macular degeneration, the leading cause of blindness in the elderly. We have a broad pipeline of novel mitochondria-targeting compounds we are evaluating for new indications, including neurodegenerative diseases. To learn more information about us and our pipeline, visit

Media Relations
dna Communications
Kate Contreras, 617-520-7088

Investor Relations
Stern Investor Relations
Rachel Frank, 212-362-1200